Short Interest in Defence Therapeutics Inc. (OTCMKTS:DTCFF) Declines By 96.6%

Defence Therapeutics Inc. (OTCMKTS:DTCFF) saw a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 100 shares, a drop of 96.6% from the February 13th total of 2,900 shares. Based on an average daily volume of 10,600 shares, the short-interest ratio is currently 0.0 days.

Defence Therapeutics Price Performance

Shares of Defence Therapeutics stock remained flat at $1.00 during trading hours on Friday. The stock had a trading volume of 1,500 shares, compared to its average volume of 20,078. The stock has a fifty day moving average of $0.73 and a 200 day moving average of $0.52. Defence Therapeutics has a 12 month low of $0.27 and a 12 month high of $1.32.

About Defence Therapeutics

Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.